Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
3.180
-0.010 (-0.31%)
Nov 20, 2024, 4:00 PM EST - Market closed
Marker Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Marker Therapeutics stock has a target of 19, which predicts an increase of 497.48% from the current stock price of 3.18.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 21, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for MRKR is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Maintains $11 → $19 | Strong Buy | Maintains | $11 → $19 | +497.48% | Oct 21, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +245.91% | Apr 30, 2024 |
| Roth Capital | Roth Capital | Strong Buy → Hold Downgrades $30 → $10 | Strong Buy → Hold | Downgrades | $30 → $10 | +214.47% | Feb 17, 2022 |
| Piper Sandler | Piper Sandler | Buy Initiates $60 | Buy | Initiates | $60 | +1,786.79% | Mar 25, 2021 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $60 | Buy | Initiates | $60 | +1,786.79% | Mar 19, 2021 |
Financial Forecast
Revenue This Year
4.50M
from 3.31M
Increased by 35.94%
Revenue Next Year
n/a
from 4.50M
EPS This Year
-1.46
from -0.94
EPS Next Year
-1.49
from -1.46
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 4.6M | n/a | n/a | ||
| Avg | 4.5M | n/a | n/a | ||
| Low | 4.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 40.0% | - | - | ||
| Avg | 35.9% | - | - | ||
| Low | 30.6% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -1.50 | -1.53 | -1.37 | |
| Avg | -1.46 | -1.49 | -1.33 | |
| Low | -1.40 | -1.43 | -1.27 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.